tweetindex
DE

Gil Morgan, MD ✓

@weoncologists · San Antonio, TX · joined 13 May 2009

Clinical Oncologist from Texas🇺🇸Director of @OncoAlert 🚨 Proudly NIH, NCI & MDA trained. An ounce of prevention equals a pound of cure. Views are own🌏

16 435Followers
7 265Following
34 249Posts total
4.8KViews on collected posts

Neueste Beiträge

The 1st Line Reset and the New Sequencing Problem — what do we want to achieve in HER2+ metastatic #BreastCancer? For the COMPLETE @OncoAlert 🚨HORIZONS VIDEO: https://t.co/eVrSunyHwy 🧑‍⚕️ Session Faculty: Dr. Javier Cortes @JavierCortesMD 🇪🇸 — International Breast Cancer 767 views · 8 likes · 4 reposts · 0 replies Open on X →
Presenting OncoAlert Horizons | Focus: Breast Cancer Educational Series 🚨 In this session, we explore: The 1st Line Reset and the New Sequencing Problem — what do we want to achieve in HER2+ metastatic #BreastCancer? For the COMPLETE VIDEO: https://t.co/8kLNLCu7aT 🧑‍⚕️ Session
2:38
2.1K views · 20 likes · 12 reposts · 0 replies Open on X →
Belgrade 🇷🇸 energy this weekend: 100+ young oncologists from Bulgaria, Croatia, Montenegro, Slovenia and Serbia at NEXTGEN Breast Academy. Huge thanks to AstraZeneca Balkans for the kind invite and to our friend Dr. Miloš Ičević, for co chairing a great session — this next http
595 views · 12 likes · 8 reposts · 0 replies Open on X →
The FDA 🇺🇸 recently granted Breakthrough Therapy Designation to Revolution Medicines' RASONQUE (daraxonrasib) combined with gemcitabine/nab-paclitaxel for treatment-naïve metastatic pancreatic adenocarcinoma, based on encouraging Phase 1/2 RMC-GI-102 data. @OncoAlert 🚨 616 views · 3 likes · 1 reposts · 0 replies Open on X →
TAISHAN-302 : In a phase 3 randomized trial of 451 patients with relapsed small-cell lung #SCLC 🫁 cancer after platinum-based therapy, tambotatug pelitecan significantly improved 📈 outcomes versus topotecan. Just out on NEJM and presented at #WCLC26 🇰🇷 #lungCancer 729 views · 4 likes · 3 reposts · 0 replies Open on X →
A pleasure to publish this at @CD_AACR w/some AMAZING @OncoAlert 🚨colleagues/friends SoMe has immense potential in ALL areas of medicine⚕️ ☑️raises awareness on trials ☑️promotes cancer prevention ☑️amplifies oncology info ☑️enables diverse viewpoints https://t.co/CoLlKTV25f h
0 views · 259 likes · 96 reposts · 16 replies Open on X →

Im Vergleich zu Konten gleicher Größe

5 Beiträge aus den letzten 90 Tagen, verglichen mit der Größenklasse 10K–100K Follower. genau im Median seiner Follower-Klasse.

Medianaufrufe729dieses Konto924Median für 10K–100K
Reichweite, %4.44%dieses Konto3.62%Median für 10K–100K
Interaktion, %1.56%dieses Konto1.52%Median für 10K–100K
KennzahlDieses KontoMedian für 10K–100KVerhältnis
Medianaufrufe pro Beitrag7299240.79×
Reichweite (Aufrufe ÷ Follower)4.44%3.62%1.23×
Interaktionsrate1.56%1.52%1.02×

Weitere Konten dieser Größe →   Mit einem anderen Konto vergleichen →   Wie diese Vergleichswerte entstehen →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

72914 Sep
61615 Sep
595
2.1K
767

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.96%14 Sep
0.65%15 Sep
3.36%
1.56%
1.56%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes61.8%47 in total
Reposts36.8%28 in total
Quotes1.3%1 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Ähnliche Konten